サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1493188

コンビネーション医薬品の市場規模、シェア、動向分析レポート：製品別、地域別、セグメント予測、2024年-2030年

Drug Device Combination Products Market Size, Share & Trends Analysis Report By Product (Transdermal Patches, Infusion Pumps, Inhalers, Drug Eluting Stents), By Region, And Segment Forecasts, 2024 - 2030

出版日
ページ情報
英文 150 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
コンビネーション医薬品の市場規模、シェア、動向分析レポート：製品別、地域別、セグメント予測、2024年-2030年
出版日: 2024年05月06日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

コンビネーション医薬品市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のコンビネーション医薬品市場規模は、2024年から2030年にかけてCAGR 9.0％を記録し、2030年には2,518億7,000万米ドルに達すると予測されています。

低侵襲技術に関連する患者の転帰の向上による需要の高まりが、この市場のインパクトの大きい促進要因です。これらの装置は早期診断を容易にし、外科手術の大部分において治療期間を短縮します。需要の高まりは、これらの機器によってもたらされる最小限の痛み、コスト効率の向上、安全性の改善、有効性の向上、迅速な回復、入院期間の短縮の結果でもあります。

市販前承認のために明確に定義されたプロトコルを施行する規制ヘルスケア当局の存在感が増していることは、メーカーが自社製品の承認を得る上で支えになると予想されます。最近、米国FDAはリーンマネジメントプロセスマッピングアプローチを取り入れ、前述の製品の審査について、よりまとまりのある、合理的で体系的かつ協力的なシステムを構築しました。これらの当局が発行する安全性ガイドラインや勧告は、将来的にこれらの製品の採用を増加させ、予測期間中の全体的な成長を後押しすると推測されます。

体内の意図しない部位での薬物吸収に起因する治療薬に関連する重篤な副作用や薬物相互作用は、標的治療の必要性を誘発し、それによって薬物とデバイスの組み合わせの需要を促進すると予想されます。例えば、レボドパの継続的な投与は、運動変動、ジスキネジア、重篤な代謝変化、神経毒性などの長期的な合併症を引き起こします。このような要因により、薬物とデバイスの組み合わせ製品のように、標的療法に基づく代替品を取り入れることが臨床的に急務となっています。

コンビネーション医薬品市場レポート・ハイライト

  • 長期治療が必要な疾患における薬剤の自己投与需要の増加により、2023年の製品別シェアは経皮吸収型貼付剤が圧倒的でした。
  • 2023年の地域別シェアでは、北米が41.31%超の最大シェアを占めたが、これは同地域の有力企業が広範な新製品開発活動を行っているためです。
  • アジア太平洋地域は、ヘルスケア支出の増加と、これらの製品の利点に関する医師の意識レベルの上昇により、今後数年間で有利な速度で成長すると予想されています。
  • 主要市場プレイヤーは、市場浸透を図るため、新製品の上市や販売提携など様々な戦略に取り組んでいます。
  • 高い運用コスト、厳しい規制の枠組み、資本要件により、新規参入業者の脅威は低いと予想されます。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 コンビネーション医薬品市場の変数と動向

  • 市場系統の見通し
  • 市場力学
    • 市場促進要因の影響分析
    • 市場抑制要因の影響分析
    • 市場機会の影響分析
  • 業界分析ツール
    • ポーターの分析
    • マクロ経済分析

第4章 コンビネーション医薬品市場：製品分析

  • 製品変動分析と市場シェア、2023年
  • 製品別
  • 輸液ポンプ
  • 整形外科コンビネーション製品
  • 光力学療法デバイス
  • 経皮パッチ
  • 薬剤溶出性ステント
  • 創傷ケア製品
  • 吸入
  • 抗菌カテーテル
  • その他

第5章 コンビネーション医薬品市場：地域推定・動向分析

  • コンビネーション医薬品市場：地域別展望
  • 北米
    • 北米のコンビネーション医薬品市場推計・予測、2018年-2030年
    • 米国
    • カナダ
  • 欧州
    • 欧州のコンビネーション医薬品市場推計・予測、2018年-2030年
    • ドイツ
    • 英国
    • フランス
  • アジア太平洋地域
    • アジア太平洋地域のコンビネーション医薬品市場推計・予測、2018年-2030年
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
  • ラテンアメリカ
    • ラテンアメリカのコンビネーション医薬品市場推計・予測、2018年-2030年
    • ブラジル
    • メキシコ
  • 中東・アフリカ
    • 中東およびアフリカのコンビネーション医薬品市場推計・予測、2018年-2030年
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第6章 競合分析

  • 企業分類
  • 参加者概要
  • 財務実績
  • 製品ベンチマーク
  • 企業市場：ポジション分析
  • 戦略マッピング
    • 合併と買収
    • パートナーシップとコラボレーション
    • 製品の発売と規制承認
    • 拡大
  • 企業プロファイル
    • Abbott
    • Terumo Medical Corporation
    • Stryker
    • Viatris Inc.
    • Medtronic
    • Boston Scientific Corporation
    • Novartis AG
    • Becton
    • Dickinson and company
    • Teleflex Incorporation

第7章 アナリストの見解

図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Drug device combination products market revenue estimates and forecast, by product, 2018 - 2030 (USD Billion)
  • Table 4 U.S. regulatory procedure for medical devices
  • Table 5 Canada regulatory procedure for medical devices
  • Table 6 Classification of medical devices

List of Figures

  • Fig. 1 Drug device combination products market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot, USD Million
  • Fig. 9 Segment snapshot (Product)
  • Fig. 10 Competitive landscape
  • Fig. 11 Drug delivery devices and drug device combination products market value, 2023 (USD million)
  • Fig. 12 Drug device combination products market dynamics
  • Fig. 13 Diabetes around the world in 2021, (Million)
  • Fig. 14 Estimated number of U.S. hospital hip and knee replacement procedures: (2021 - 2022)
  • Fig. 15 Drug device combination products market: PORTER's analysis
  • Fig. 16 Drug device combination products market: PESTEL analysis
  • Fig. 17 Drug device combination product market: Product outlook and key takeaways
  • Fig. 18 Drug device combination products market, by product: Market share, 2023 & 2030
  • Fig. 19 Infusion pumps market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Volumetric market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Disposables market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Syringes market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Ambulatory market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Implantable market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Insulin market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Orthopedic combination products market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Bone graft implants market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Antibiotic bone cement market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Photodynamic therapy devices market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Transdermal patches market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Drug eluting stents market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Coronary stents market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Peripheral vascular stents market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Wound care products market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Inhalers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Dry powder market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Nebulizers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Metered dose market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Antimicrobial catheters market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Urological market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Cardiovascular market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Drug device combination products market revenue, by region, 2023 & 2030 (USD Billion)
  • Fig. 45 Regional marketplace: Key takeaways
  • Fig. 46 North America drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Key country dynamics
  • Fig. 48 Reimbursement procurement process
  • Fig. 49 US drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Key country dynamics
  • Fig. 51 Canada drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Europe drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Key country dynamics
  • Fig. 54 Germany drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 UK drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 France drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Asia Pacific drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Key country dynamics
  • Fig. 61 Reimbursement procurement process
  • Fig. 62 Japan drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Key country dynamics
  • Fig. 64 China drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Key country dynamics
  • Fig. 66 India drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Key country dynamics
  • Fig. 68 Australia drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Key country dynamics
  • Fig. 70 South Korea drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Latin America drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 Brazil drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 Mexico drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Middle East & Africa drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Key country dynamics
  • Fig. 78 South Africa drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Key country dynamics
  • Fig. 80 Saudi Arabia drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Key country dynamics
  • Fig. 82 UAE drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Key country dynamics
  • Fig. 84 Kuwait drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Key company categorization
  • Fig. 86 Company market position analysis
  • Fig. 87 Strategy mapping
目次
Product Code: GVR-1-68038-260-0

Drug Device Combination Products Market Growth & Trends:

The global drug device combination products market size is expected to reach USD 251.87 billion by 2030, registering a CAGR of 9.0% from 2024 to 2030, according to a new report by Grand View Research, Inc. Rising demand for minimally invasive techniques due to enhanced patient outcomes associated with it is the high impact-rendering driver of this market. These devices facilitate early diagnosis and reduce treatment duration in a majority of surgical procedures. Growing demand is also a consequence of minimal pain, heightened cost efficiency, improved safety, better efficacy, rapid recovery, and reduced hospital stay rendered by these devices.

Increasing presence of regulatory healthcare authorities enforcing clearly defined protocols for premarket authorizations is anticipated to support manufacturers in gaining approvals for their products. Recently, the U.S. FDA incorporated the lean management process mapping approach to build a more cohesive, streamlined, systematic, and collaborative system for the review of the aforementioned products. Safety guidelines and recommendations issued by these authorities are presumed to increase the adoption of these products in future and boost overall growth during the forecast period.

Severe side effects and drug interactions associated with therapeutics owing to drug absorption by unintended sites in the body are anticipated to induce need for targeted therapy, thereby propelling demand for drug-device combinations. For instance, consistent administration of Levodopa results in long-term complications such as motor fluctuations, dyskinesias, severe metabolic changes, and neurotoxic effects. These aforementioned factors drive the clinical urgency to incorporate alternatives based on targeted therapy, as in case of drug-device combination products.

Drug Device Combination Products Market Report Highlights:

  • Transdermal patch held the dominant share by product in 2023 owing to increasing demand for self-administration of drugs in diseases requiring long-term treatment
  • North America held the largest share of over 41.31% in 2023 in terms of region owing to extensive new product development activities conducted by prominent players across this region
  • Asia Pacific is anticipated to grow at a lucrative rate over the coming years owing to increasing healthcare spending and rising awareness levels of physicians pertaining to benefits of these products
  • Key market players are engaged in various strategies such as new product launch and distribution agreements to gain market penetration
  • High operational cost, stringent regulatory framework, and capital requirement keep entry barriers at a higher level, owing to which, threat of new entrants is expected to be low.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation
  • 1.2. Market Definition
    • 1.2.1. Product
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Abbreviations
  • 1.10. Objectives
    • 1.10.1. Objectives 1
    • 1.10.2. Objectives 2
    • 1.10.3. Objectives 3

Chapter 2. Executive Summary

  • 2.1. Market Snapshot (Regional)
  • 2.2. Segment Snapshot (Product)
  • 2.3. Competitive Landscape

Chapter 3. Drug Device Combination Products Market Variables, and Trends

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver impact analysis
      • 3.2.1.1. Increasing demand for minimally invasive drug delivery devices
      • 3.2.1.2. Technological advancements
      • 3.2.1.3. Increasing prevalence of chronic diseases
    • 3.2.2. Market Restraint Impact Analysis
      • 3.2.2.1. High cost associated with drug device combination products
      • 3.2.2.2. Technical challenges in drug delivery
      • 3.2.2.3. Increasing prevalence of chronic diseases
    • 3.2.3. Market Opportunity Impact Analysis
      • 3.2.3.1. Growing adherence rate
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's analysis
    • 3.3.2. Macroeconomics analysis

Chapter 4. Drug Device Combination Product Market: Product Analysis

  • 4.1. Product Movement Analysis & Market Share, 2023
  • 4.2. Drug Device Combination Products Market: Estimates & Forecast, By Product (USD Billion)
    • 4.2.1. Infusion Pumps
      • 4.2.1.1. Infusion pumps market, 2018 - 2030 (USD Million)
      • 4.2.1.2. Volumetric
      • 4.2.1.2.1. Volumetric market, 2018 - 2030 (USD Million)
      • 4.2.1.3. Disposables
      • 4.2.1.3.1. Disposables market, 2018 - 2030 (USD Million)
      • 4.2.1.4. Syringes
      • 4.2.1.4.1. Syringes market, 2018 - 2030 (USD Million)
      • 4.2.1.5. Ambulatory
      • 4.2.1.5.1. Ambulatory market, 2018 - 2030 (USD Million)
      • 4.2.1.6. Implantable
      • 4.2.1.6.1. Implantable market, 2018 - 2030 (USD Million)
      • 4.2.1.7. Insulin
      • 4.2.1.7.1. Insulin market, 2018 - 2030 (USD Million)
    • 4.2.2. Orthopedic combination products
      • 4.2.2.1. Orthopedic combination product market, 2018 - 2030 (USD Million)
      • 4.2.2.2. Bone Graft Implants
      • 4.2.2.2.1. Bone graft implant market, 2018 - 2030 (USD Million)
      • 4.2.2.3. Antibiotic Bone Cement
      • 4.2.2.3.1. Antibiotic bone cement market, 2018 - 2030 (USD Million)
    • 4.2.3. Photodynamics therapy devices
      • 4.2.3.1. Photodynamics therapy devices market, 2018 - 2030 (USD Million)
    • 4.2.4. Transdermal patches
      • 4.2.4.1. Transdermal patches market, 2018 - 2030 (USD Million)
    • 4.2.5. Drug eluting stents
      • 4.2.5.1. Drug eluting stents market, 2018 - 2030 (USD Million)
      • 4.2.5.2. Coronary Stents
      • 4.2.5.2.1. Coronary Stents market, 2018 - 2030 (USD Million)
      • 4.2.5.3. Peripheral vascular stents
      • 4.2.5.3.1. Peripheral vascular stents market, 2018 - 2030 (USD Million)
    • 4.2.6. Wound care products
      • 4.2.6.1. Wound care product market, 2018 - 2030 (USD Million)
    • 4.2.7. Inhalers
      • 4.2.7.1. Inhalers market, 2018 - 2030 (USD Million)
      • 4.2.7.2. Dry powder
      • 4.2.7.2.1. Dry powder market, 2018 - 2030 (USD Million)
      • 4.2.7.3. Nebulizers
      • 4.2.7.3.1. Nebulizers market, 2018 - 2030 (USD Million)
      • 4.2.7.4. Metered Dose
      • 4.2.7.4.1. Metered Dose market, 2018 - 2030 (USD Million)
    • 4.2.8. Antimicrobial catheters
      • 4.2.8.1. Antimicrobial catheters market, 2018 - 2030 (USD Million)
      • 4.2.8.2. Urological
      • 4.2.8.2.1. Urological market, 2018 - 2030 (USD Million)
      • 4.2.8.3. Cardiovascular
      • 4.2.8.3.1. Cardiovascular market, 2018 - 2030 (USD Million)
      • 4.2.8.4. Others
      • 4.2.8.4.1. Others market, 2018 - 2030 (USD Million)
    • 4.2.9. Others
      • 4.2.9.1. Others market, 2018 - 2030 (USD Million)

Chapter 5. Drug Device Combination Products Market: Regional Estimates & Trend Analysis

  • 5.1. Drug Device Combination Products Market: Regional Outlook
  • 5.2. North America
    • 5.2.1. North America drug device combination products market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.2.2. U.S.
      • 5.2.2.1. Key country dynamics
      • 5.2.2.2. Competitive scenario
      • 5.2.2.3. Regulatory scenario
      • 5.2.2.4. Reimbursement scenario
      • 5.2.2.5. U.S. drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.2.3. Canada
      • 5.2.3.1. Key country dynamics
      • 5.2.3.2. Competitive scenario
      • 5.2.3.3. Regulatory scenario
      • 5.2.3.4. Reimbursement scenario
      • 5.2.3.5. Canada drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.3. Europe
    • 5.3.1. Europe drug device combination products market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.3.2. Germany
      • 5.3.2.1. Key country dynamics
      • 5.3.2.2. Competitive scenario
      • 5.3.2.3. Regulatory scenario
      • 5.3.2.4. Reimbursement scenario
      • 5.3.2.5. Germany drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.3.3. UK
      • 5.3.3.1. Key country dynamics
      • 5.3.3.2. Competitive scenario
      • 5.3.3.3. Regulatory scenario
      • 5.3.3.4. Reimbursement scenario
      • 5.3.3.5. UK drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.3.4. France
      • 5.3.4.1. Key country dynamics
      • 5.3.4.2. Competitive scenario
      • 5.3.4.3. Regulatory scenario
      • 5.3.4.4. Reimbursement scenario
      • 5.3.4.5. France drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.4. Asia Pacific
    • 5.4.1. Asia Pacific drug device combination products market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.4.2. Japan
      • 5.4.2.1. Key country dynamics
      • 5.4.2.2. Competitive scenario
      • 5.4.2.3. Regulatory scenario
      • 5.4.2.4. Reimbursement scenario
      • 5.4.2.5. Japan drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.4.3. China
      • 5.4.3.1. Key country dynamics
      • 5.4.3.2. Competitive scenario
      • 5.4.3.3. Regulatory scenario
      • 5.4.3.4. Reimbursement scenario
      • 5.4.3.5. China drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.4.4. India
      • 5.4.4.1. Key country dynamics
      • 5.4.4.2. Competitive scenario
      • 5.4.4.3. Regulatory scenario
      • 5.4.4.4. Reimbursement scenario
      • 5.4.4.5. India drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.4.5. Australia
      • 5.4.5.1. Key country dynamics
      • 5.4.5.2. Competitive scenario
      • 5.4.5.3. Regulatory scenario
      • 5.4.5.4. Reimbursement scenario
      • 5.4.5.5. Australia drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.4.6. South Korea
      • 5.4.6.1. Key country dynamics
      • 5.4.6.2. Competitive scenario
      • 5.4.6.3. Regulatory scenario
      • 5.4.6.4. Reimbursement scenario
      • 5.4.6.5. South Korea drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5. Latin America
    • 5.5.1. Latin America drug device combination products market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.5.2. Brazil
      • 5.5.2.1. Key country dynamics
      • 5.5.2.2. Competitive scenario
      • 5.5.2.3. Regulatory scenario
      • 5.5.2.4. Reimbursement scenario
      • 5.5.2.5. Brazil drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.5.3. Mexico
      • 5.5.3.1. Key country dynamics
      • 5.5.3.2. Competitive scenario
      • 5.5.3.3. Regulatory scenario
      • 5.5.3.4. Reimbursement scenario
      • 5.5.3.5. Mexico drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6. Middle East & Africa
    • 5.6.1. Middle East & Africa drug device combination products market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.6.2. South Africa
      • 5.6.2.1. Key country dynamics
      • 5.6.2.2. Competitive scenario
      • 5.6.2.3. Regulatory scenario
      • 5.6.2.4. Reimbursement scenario
      • 5.6.2.5. South Africa drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.6.3. Saudi Arabia
      • 5.6.3.1. Key country dynamics
      • 5.6.3.2. Competitive scenario
      • 5.6.3.3. Regulatory scenario
      • 5.6.3.4. Reimbursement scenario
      • 5.6.3.5. Saudi Arabia drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.6.4. UAE
      • 5.6.4.1. Key country dynamics
      • 5.6.4.2. Competitive scenario
      • 5.6.4.3. Regulatory scenario
      • 5.6.4.4. Reimbursement scenario
      • 5.6.4.5. UAE drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.6.5. Kuwait
      • 5.6.5.1. Key country dynamics
      • 5.6.5.2. Competitive scenario
      • 5.6.5.3. Regulatory scenario
      • 5.6.5.4. Reimbursement scenario
      • 5.6.5.5. Kuwait drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. Competitive Analysis

  • 6.1. Company Categorization
  • 6.2. Participant Overview
  • 6.3. Financial Performance
  • 6.4. Product Benchmarking
  • 6.5. Company Market: Position Analysis
  • 6.6. Strategy Mapping
    • 6.6.1. Mergers & acquisitions
    • 6.6.2. Partnerships & collaborations
    • 6.6.3. Product launch & regulatory approval
    • 6.6.4. Expansion
  • 6.7. Company Profiles
    • 6.7.1. Abbott
      • 6.7.1.1. Company Overview
      • 6.7.1.2. Financial Performing
      • 6.7.1.3. Product Benchmarking
      • 6.7.1.4. Strategic Initiatives
    • 6.7.2. Terumo Medical Corporation
      • 6.7.2.1. Company Overview
      • 6.7.2.2. Financial Performing
      • 6.7.2.3. Product Benchmarking
      • 6.7.2.4. Strategic Initiatives
    • 6.7.3. Stryker
      • 6.7.3.1. Company Overview
      • 6.7.3.2. Financial Performing
      • 6.7.3.3. Product Benchmarking
      • 6.7.3.4. Strategic Initiatives
    • 6.7.4. Viatris Inc.
      • 6.7.4.1. Company Overview
      • 6.7.4.2. Financial Performing
      • 6.7.4.3. Product Benchmarking
      • 6.7.4.4. Strategic Initiatives
    • 6.7.5. Medtronic
      • 6.7.5.1. Company Overview
      • 6.7.5.2. Financial Performing
      • 6.7.5.3. Product Benchmarking
      • 6.7.5.4. Strategic Initiatives
    • 6.7.6. Boston Scientific Corporation
      • 6.7.6.1. Company Overview
      • 6.7.6.2. Financial Performing
      • 6.7.6.3. Product Benchmarking
      • 6.7.6.4. Strategic Initiatives
    • 6.7.7. Novartis AG
      • 6.7.7.1. Company Overview
      • 6.7.7.2. Financial Performing
      • 6.7.7.3. Product Benchmarking
      • 6.7.7.4. Strategic Initiatives
    • 6.7.8. Becton
      • 6.7.8.1. Company Overview
      • 6.7.8.2. Financial Performing
      • 6.7.8.3. Product Benchmarking
      • 6.7.8.4. Strategic Initiatives
    • 6.7.9. Dickinson and company
      • 6.7.9.1. Company Overview
      • 6.7.9.2. Financial Performing
      • 6.7.9.3. Product Benchmarking
      • 6.7.9.4. Strategic Initiatives
    • 6.7.10. Teleflex Incorporation
      • 6.7.10.1. Company Overview
      • 6.7.10.2. Financial Performing
      • 6.7.10.3. Product Benchmarking
      • 6.7.10.4. Strategic Initiatives

Chapter 7. Analysis Perspective